Risk Factors Update Summary
- The company received approval for AGAMREE® for Duchenne Muscular Dystrophy, diversifying its product portfolio.
- The company invested significantly in acquiring and developing new drug products, expanding its market presence.
- The company faces potential challenges in managing growth, impacting operational results and financial standing.
- The company relies on third parties for manufacturing, with disruptions potentially costing approximately $0.5 million.
- The company's success depends on maintaining effective sales, marketing, and distribution capabilities.
- The company's ability to compete effectively relies on obtaining and enforcing intellectual property rights.
- The company faces risks related to cybersecurity threats, engaging external experts to evaluate and enhance risk management.
Full Text Changes in Most Recent 10-K
Intended use: review the highlighted statements. These are additions to the risk factors disclosure in the most recent 10-K filing compared to the previous 10-K filing. Deleted and moved text is less important and is shown for context.
To view the full company filings, click on the following link to be taken to the SEC EDGAR database landing page for the company: https://www.sec.gov/edgar/browse/?CIK=1369568&owner=exclude
This content requires a 'Free' membership to view. Please create one here.
This content requires a 'Free' membership to view. Please create one here.